

## Supplementary Online Content

Pedersen AB, Heide-Jørgensen U, Sørensen HT, Prieto-Alhambra D, Ehrenstein

V. Comparison of risk of osteoporotic fracture in denosumab vs alendronate

treatment within 3 years of initiation. *JAMA Netw Open*. 2019;2(4):e192416.

doi:10.1001/jamanetworkopen.2019.2416

**eTable 1.** Rates and hazard ratios of the fracture outcomes in initiators of denosumab and alendronate, defining initiation by requiring 5 years' absence of osteoporosis treatment before the index date (sensitivity analysis)

**eTable 2.** Rates and hazard ratios of the fracture outcomes for denosumab and alendronate, with follow-up censored at discontinuation or switch

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Rates and hazard ratios of the fracture outcomes in initiators of denosumab and alendronate, defining initiation by requiring 5 years' absence of osteoporosis treatment before the index date (sensitivity analysis).

Analysis group	Cohort	N	Cases	PY <sup>a</sup>	Crude rate per 1,000 PY	Crude hazard	IPTW <sup>b</sup> hazard
					(95% CI)	ratio (95% CI)	ratio (95% CI)
Hip fracture	Denosumab	3,703	148	12,829.6	11.5 (9.8 - 13.6)	1.12 (0.95 - 1.32)	1.07 (0.88 - 1.30)
	Alendronate	83,110	2,841	274,546.6	10.3 (10.0 - 10.7)	Reference	Reference
Any fracture	Denosumab	3,703	374	12,274.5	30.5 (27.5 - 33.7)	0.95 (0.86 - 1.05)	0.93 (0.82 - 1.05)
	Alendronate	83,110	8,409	262,158.1	32.1 (31.4 - 32.8)	Reference	Reference

<sup>a</sup> PY- person years. <sup>b</sup> IPTW - inverse probability of treatment weight.

eTable 2. Rates and hazard ratios of the fracture outcomes for denosumab and alendronate, with follow-up censored at discontinuation or switch.

Analysis group	Cohort	N	Cases	PY	Crude rate per 1,000	Crude hazard ratio	IPTW hazard ratio
					PY (95% CI)	(95% CI)	(95% CI)
Hip fracture	Denosumab	4,624	122	11,633.2	10.5 (8.7 - 12.5)	1.01 (0.84 - 1.22)	0.88 (0.71 - 1.09)
	Alendronate	87,731	1,785	166,022.4	10.8 (10.3 - 11.3)	Reference	Reference
Any fracture	Denosumab	4,624	339	11,198.1	30.3 (27.1 - 33.7)	0.93 (0.83 - 1.03)	0.85 (0.75 - 0.97)
	Alendronate	87,731	5,438	160,218.3	33.9 (33.0 - 34.9)	Reference	Reference

<sup>a</sup> PY- person years. <sup>b</sup> IPTW - inverse probability of treatment weight.